Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Short Interest Down 39.2% in July

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 2,470,000 shares, adeclineof39.2% from the July 15th total of 4,060,000 shares. Currently,3.0% of the company's stock are sold short. Based on an average trading volume of 3,400,000 shares, the days-to-cover ratio is presently 0.7 days. Based on an average trading volume of 3,400,000 shares, the days-to-cover ratio is presently 0.7 days. Currently,3.0% of the company's stock are sold short.

Insider Transactions at Verona Pharma PLC American Depositary Share

In other Verona Pharma PLC American Depositary Share news, Director Lisa Deschamps sold 9,464 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $124,356.96. Following the completion of the sale, the director directly owned 84,856 shares of the company's stock, valued at approximately $1,115,007.84. This represents a 10.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Mark W. Hahn sold 208,912 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $2,745,103.68. Following the completion of the sale, the chief financial officer owned 12,464,968 shares of the company's stock, valued at approximately $163,789,679.52. This trade represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,220,584 shares of company stock worth $24,613,268. 4.80% of the stock is owned by insiders.

Institutional Trading of Verona Pharma PLC American Depositary Share

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. grew its position in shares of Verona Pharma PLC American Depositary Share by 2.2% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 3,457,850 shares of the company's stock valued at $219,539,000 after purchasing an additional 73,900 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Verona Pharma PLC American Depositary Share by 1.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,866,280 shares of the company's stock worth $118,491,000 after acquiring an additional 32,748 shares during the last quarter. RTW Investments LP bought a new position in Verona Pharma PLC American Depositary Share in the 4th quarter worth about $84,568,000. Janus Henderson Group PLC raised its holdings in shares of Verona Pharma PLC American Depositary Share by 59.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock valued at $77,466,000 after acquiring an additional 624,370 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in shares of Verona Pharma PLC American Depositary Share by 381.9% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,631,000 shares of the company's stock valued at $103,552,000 after acquiring an additional 1,292,575 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of Verona Pharma PLC American Depositary Share stock traded down $0.35 during trading hours on Thursday, reaching $105.45. The company had a trading volume of 2,917,638 shares, compared to its average volume of 1,749,761. The firm has a market cap of $8.98 billion, a PE ratio of -106.51 and a beta of 0.12. Verona Pharma PLC American Depositary Share has a one year low of $24.50 and a one year high of $105.85. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54. The business has a fifty day simple moving average of $100.64 and a 200 day simple moving average of $78.64.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $0.14. The business had revenue of $103.14 million for the quarter, compared to analysts' expectations of $90.41 million. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%. On average, analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on VRNA shares. Cantor Fitzgerald increased their price target on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. BTIG Research lowered Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Zacks Research raised shares of Verona Pharma PLC American Depositary Share to a "hold" rating in a report on Friday, August 8th. Cowen lowered shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Finally, Truist Financial lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Two investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.